UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Volltextzugriff (PDF)

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Annual review of medicine, 2004-01, Vol.55 (1), p.433-457

Rowinsky, Eric K

2004

Volltextzugriff (PDF)

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Volltextzugriff (PDF)

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Volltextzugriff (PDF)

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Volltextzugriff (PDF)

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

Haematologica (Roma), 2015-02, Vol.100 (2), p.223-230

2015

Volltextzugriff (PDF)

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Clinical cancer research, 2007-09, Vol.13 (18), p.5549s-5555s

2007

Volltextzugriff (PDF)

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Volltextzugriff (PDF)

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Volltextzugriff (PDF)

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Clinical cancer research, 2007-09, Vol.13 (18), p.5544s-5548s

2007

Volltextzugriff (PDF)

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Clinical cancer research, 2010-02, Vol.16 (4), p.1191-1205

2010

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Volltextzugriff (PDF)

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

Annual review of medicine, 1997-01, Vol.48 (1), p.353-374

Rowinsky, MD, Eric K

1997

Volltextzugriff (PDF)

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6663-6673

2008

Volltextzugriff (PDF)

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

British journal of haematology, 2014-09, Vol.166 (6), p.862-874

2014

Volltextzugriff (PDF)

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Clinical cancer research, 2008-12, Vol.14 (23), p.7884-7895

2008

Volltextzugriff (PDF)

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Oncogene, 2000-12, Vol.19 (56), p.6680-6686

2000

Volltextzugriff (PDF)

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Clinical cancer research, 2010-03, Vol.16 (6), p.1915-1923

2010

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

JAMA oncology, 2024-09

2024

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Clinical and translational science, 2024-03, Vol.17 (3), p.e13750-n/a

2024

Volltextzugriff (PDF)

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

The oncologist (Dayton, Ohio), 2003-12, Vol.8 (S3), p.5-17

Rowinsky, Eric K.

2003

Volltextzugriff (PDF)

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Volltextzugriff (PDF)

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Clinical cancer research, 2010-11, Vol.16 (22), p.5591-5602

2010

Volltextzugriff (PDF)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

1 – 25 von 212

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(194)
Mit Volltextzugriff
(202)

Publikationsform

Sprache

Englisch
(212)

Erscheinungsjahr

n.n

Thema

Humans
(135)
Oncology
(117)
Life Sciences & Biomedicine
(116)
Science & Technology
(116)
Biological And Medical Sciences
(95)
Medical Sciences
(95)
Antineoplastic Agents
(89)
Pharmacology. Drug Treatments
(88)
Female
(80)
Male
(78)
Middle Aged
(76)
Aged
(74)
Adult
(72)
Neoplasms - Drug Therapy
(61)
Chemotherapy
(51)
Dose-Response Relationship, Drug
(46)
Antineoplastic Agents - Therapeutic Use
(36)
Tumors
(33)
Drug Administration Schedule
(28)
Treatment Outcome
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

Aktive Filter

Suchergebnisse filtern